| CIHR Institutes |
| ICR Home |
| About ICR |
| Research Priorities |
| Scientific Director |
| Advisory Board |
| Facts & Figures |
| ICR Funding |
| ICR Publications & Resources |
| Contact ICR |
Dr. Philip Branton obtained his PhD in 1972 at the Ontario Cancer Institute, Department of Medical Biophysics, University of Toronto. Following post-doctoral studies at the Massachusetts Institute of Technology (MIT) with Phillips W. Robbins he became an associate professor in the Département de biologie céllulaire at the Université de Sherbrooke. In 1975 he moved to the Cancer Research Group at McMaster University where he became Associate, then Full Professor of Pathology, and in 1987, he was named the Group's Coordinator. He moved to McGill University as Chair of the Department of Biochemistry (1990-2000), and in 1996 was named Gilman Cheney Professor of Biochemistry. He has served the Medical Research Council (MRC) as panel member, National Cancer Institute of Canada (NCIC) as panel member/chair Advisory Committee on Research, Canadian Breast Cancer Research Initiative (CBCRI) and other agencies in Canada and the USA in many capacities, and has been active in both university and hospital based research. He is also the Co-Founder of GeminiX Biotechnologies Inc. of Montreal and is known for basic research on viruses, apoptosis and tumour suppressors, and for applied work on new cancer therapies.
Term end: December 31, 2007
